Micell Forms Alliance for the Development of Drug-Eluting Stents, Balloons


January 13, 2009

January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing innovative interventional cardiology systems, has obtained the rights to Maxcor's CE-marked Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of developing and marketing drug-eluting stents (DES) based on Micell's prop coating technology.

The companies also entered into an agreement to develop drug-eluting balloon (DEB) products for cardiovascular applications.

Micell has developed a drug-polymer formulation that is said to precisely and consistently control drug elution and the duration of polymer exposure. The coating has the potential to deliver a precise therapeutic solution for coronary artery disease without the long-term safety concerns of currently available DES. The in-licensing of the Genius MAGIC Cobalt Chromium Coronary Stent System provides what the company believes is the optimal bare-metal stent product for the further development of the company's drug-polymer coating. The company believes that DEB will advance the treatment of many clinical conditions while minimizing risks or side-effects of these treatments.

For more information: www.micell.com